Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

O'Key's revenues in the 1st half of the year grew by 6.2%

7/31/24 OKEY

MD Medical increased revenue by 23%

7/31/24 MDMG

Bashinformsvyaz reported for 6 months of 2024 by RAS

7/31/24 BISVP

Belon reported for 6 months of 2024 by RAS

7/31/24 BLNG

Rosseti Siberia reported for 6 months of 2024 by RAS

7/31/24 MRKS

Board of Directors of IMCB recommended dividends

7/30/24 GEMA

Gazprom reported for 6 months of 2024 by RAS

7/30/24 GAZP

Yuzhuralzoloto reported for 6 months of 2024 by RAS

7/30/24 UGLD

Forward Energy reported for 6 months of 2024

7/30/24 TGKJ

RBC reports for 6 months of 2024 by RAS

7/30/24 RBCM